Acquired von willebrand syndrome secondary to monoclonal gammopathy of undetermined significance: long-term remission after treatment with bortezomib

Imagem de Miniatura
Arquivos
art_SALDANHA_Acquired_von_willebrand_syndrome_secondary_to_monoclonal_gammopathy_2023.PDF (906.51 KB)
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER
Autores
Citação
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, v.55, n.4, p.770-774, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Monoclonal gammopathy of undetermined significance (MGUS) is a plasma cell disorder that can precede the diagnosis of multiple myeloma. MGUS is characterized by the presence of a monoclonal paraprotein without evidence of multiple myeloma or other lymphoplasmacytic malignancies. Even though MGUS is an asymptomatic condition that does not require management strategies other than periodic follow-up to prevent complications, secondary nonmalignant diseases may arise, requiring control of the plasma cell clone. Acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder that occurs in patients with no prior personal or family history of bleeding. It is associated with several other disorders, such as neoplasia, mainly hematological (including MGUS and other lymphoproliferative disorders), autoimmune, infectious and cardiac diseases. At diagnosis, patients usually present with cutaneous and mucosal bleeding, including gastrointestinal bleeding. Here, we report a case of a patient with MGUS who developed AVWS after one year of follow-up. The patient was refractory to glucocorticoids and cyclophosphamide and achieved remission only after monoclonal paraprotein was eradicated following treatment with bortezomib and dexamethasone. Our report sdemonstrates that, for refractory cases, eradication of the monoclonal paraprotein may be necessary to treat bleeding complications due to MGUS-associated AVWS.
Palavras-chave
von Willebrand factor, Multiple myeloma, Bleeding coagulation disorders, Factor VIII, Paraproteinemias
URI
https://observatorio.fm.usp.br/handle/OPI/53774
Referências
  1. Abou-Ismail MY, 2021, RES PRACT THROMB HAE, V5, P356, DOI 10.1002/rth2.12481
  2. Atkin C, 2018, CLIN MED, V18, P391, DOI 10.7861/clinmedicine.18-5-391
  3. Dane KE, 2021, BLOOD ADV, V5, P2813, DOI 10.1182/bloodadvances.2021004843
  4. Engelen ET, 2015, HAEMOPHILIA, V21, P419, DOI 10.1111/hae.12701
  5. Federici AB, 2000, THROMB HAEMOSTASIS, V84, P345
  6. Federici AB, 1998, BLOOD, V92, P2707, DOI 10.1182/blood.V92.8.2707.420k25_2707_2711
  7. Federici AB, 2013, SEMIN THROMB HEMOST, V39, P191, DOI 10.1055/s-0033-1334867
  8. Franchini M, 2020, HAEMATOLOGICA, V105, P2032, DOI 10.3324/haematol.2020.255117
  9. Go RS, 2018, BLOOD, V131, P163, DOI 10.1182/blood-2017-09-807560
  10. Katagiri S, 2016, HAEMOPHILIA, V22, pE557, DOI 10.1111/hae.13077
  11. Kyle RA, 2006, NEW ENGL J MED, V354, P1362, DOI 10.1056/NEJMoa054494
  12. Lamboley V, 2002, JOINT BONE SPINE, V69, P62, DOI 10.1016/S1297-319X(01)00343-8
  13. Lavin M, 2016, J THROMB HAEMOST, V14, P1200, DOI 10.1111/jth.13317
  14. Ojeda-Uribe M, 2010, AM J HEMATOL, V85, P396, DOI 10.1002/ajh.21692
  15. Voisin S, 2011, MEDICINE, V90, P404, DOI 10.1097/MD.0b013e3182397166

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/31